Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gemcitabine × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 616 Cholangiocarcinoma 97 Biliary Tract Neoplasms 82 Neoplasms 61 Neoplasm Metastasis 57 Gallbladder Neoplasms 54 Colorectal Neoplasms 43 Bile Duct Neoplasms 36 Carcinoma, Non-Small-Cell Lung 32 Adenocarcinoma 25 Carcinoma, Hepatocellular 22 Stomach Neoplasms 19 Liver Neoplasms 18 Colonic Neoplasms 18 Ovarian Neoplasms 17 Lung Neoplasms 16 Breast Neoplasms 16 Carcinoma, Pancreatic Ductal 15 Esophageal Neoplasms 13 Rectal Neoplasms 12 Sarcoma 10 Pancreatic Adenocarcinoma 10 Carcinoma 10 Urinary Bladder Neoplasms 9 Small Cell Lung Carcinoma 9 Gastrointestinal Neoplasms 9 Prostatic Neoplasms 8 Pancreatic Diseases 8 Squamous Cell Carcinoma of Head and Neck 7 Recurrence 7

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡